The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
NCRI 2016 | Challenges with drug combinations
Andreas Strasser, MSc, PhD of the The Walter and Eliza Hall Institute, Parkville, Australia, discusses the combination of drugs for the treatment of cancer at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK. Prof. Strasser starts by explaining that most cancer therapies that actually work are multi-drug treatment therapies. These BH3 mimetics as these drugs are called, will only rarely work as a single agent in a therapeutic setting. The Bcl-2 inhibitor in chronic lymphocytic leukemia (CLL) is probably going to be the only one where this will happen. Therefore, these drugs will mostly be used in combination with existing therapies. He believes that they will work best in combination with the so called inhibitors of oncogenic kinases such as the BRAF inhibitor, MIF inhibitor in melanoma or the EGFR inhibitors in lung cancers and many others of these types of drugs.
